HENGENIX
Hengenix is a biotechnology research company. Their research includes chronic and life-threatening diseases in oncology and autoimmune diseases. They discover and develop antibody drugs in addition to providing clinical, regulatory, and commercial planning by research and development from multinational biopharmaceutical companies.
HENGENIX
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Milpitas, California, United States
Country:
United States
Website Url:
http://www.hengenix.com
Total Employee:
11+
Status:
Active
Contact:
+1 510 445 0305
Email Addresses:
[email protected]
More informations about "Hengenix"
etranacogene dezaparvovec | CDA-AMC
Sep 26, 2024 HEMGENIX (etranacogene dezaparvovec) is indicated for treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital Factor IX deficiency) who …See details»
HEMGENIX® (etranacogene dezaparvovec-drlb) | Official Patient …
HEMGENIX ®, etranacogene dezaparvovec-drlb, is a one-time gene therapy for the treatment of adults with hemophilia B who:. Currently use Factor IX prophylaxis therapy, or; Have current or …See details»
Hengenix - Crunchbase Company Profile & Funding
Hengenix is a biotechnology research company. Their research includes chronic and life-threatening diseases in oncology and autoimmune diseases.See details»
Update on hemophilia gene therapy in Canada
Mar 26, 2024 Hemgenix has also been approved by regulators in Europe and the U.S. In late December 2023, a second gene therapy for hemophilia B was approved by Canadian …See details»
Etranacogene dezaparvovec - Wikipedia
Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy which consists of a viral vector carrying a gene for clotting Factor IX. The gene is expressed in the liver to produce Factor IX protein, to increase blood levels of Factor IX and thereby limit bleeding episodes. Hemophilia B is a genetic bleeding disorder resulting from missing or ins…See details»
Health Canada approves Hemgenix gene therapy for hemophilia B
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the …See details»
CSL Behring Announces Positive Reimbursement Decision in …
Ottawa, ON – July 16, 2024 – CSL Behring Canada Inc., a business unit of global biotechnology leader CSL, today announced that the Canadian Agency for Drugs and Technologies in Health …See details»
Hengenix - Contacts, Employees, Board Members, Advisors
Hengenix is a biotechnology company. AI Content may contain mistakes and is not legal, financial or investment advice.See details»
Etranacogene Dezaparvovec (Hemgenix) - NCBI Bookshelf
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed …See details»
Hengenix Biotech - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
Health Canada Authorizes CSL's HEMGENIX as First Gene Therapy …
HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in …See details»
CADTH Reimbursement Review CADTH Reimbursement …
Etranacogene dezaparvovec (Hemgenix) 2 Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health …See details»
HEMGENIX® (etranacogene dezaparvovec-drlb) | How HEMGENIX …
2 days ago HEMGENIX is the first‑ever gene therapy for hemophilia B. HEMGENIX uses a gene therapy approach called gene transfer. This approach aims to introduce a working, or …See details»
CSL dedicated to Hemgenix as it turns back on lenti-based gene ...
Nov 20, 2024 Importantly, Hemgenix is an in vivo adeno-associated viral-based (AAV-based) gene therapy, rather than ex vivo lentiviral-based. Thus, CSL will still focus on gene therapies …See details»
HEMGENIX Has Been Administered Across The U.S.
Jul 31, 2024 Approved by the FDA in 2022, HEMGENIX has been the focus of extensive research for many years, promising new hope for patients. We are thrilled to highlight a …See details»
Hengenix Biotech - Overview, News & Similar companies - ZoomInfo
Oct 3, 2023 Who is Hengenix Biotech. At Hengenix Biotech, we take pride in each and every one of our team members. We are committed to the talent and career development of our …See details»
U.S. Food and Drug Administration approves CSL's HEMGENIX ...
Nov 22, 2022 HEMGENIX may lead to elevations of liver enzymes in the blood; therefore, ultrasound and other testing will be performed to check on liver health before HEMGENIX can …See details»
Hengenix, A Henlius Company - Facebook
Hengenix, A Henlius Company. 1,583 likes. We focus on developing and delivering high-quality, innovative, and affordable medical solutions.See details»
HEMGENIX offers elevated and sustained factor IX
The value of HEMGENIX. For a 1-million-member plan, it is estimated that 2 patients may qualify for HEMGENIX. † According to ICER’s analysis, HEMGENIX was projected to be a dominant …See details»
EU gets first hemophilia B gene therapy - Nature Biotechnology
Apr 17, 2023 In the USA, Hemgenix was approved by the Food and Drug Administration in November 2022, with its price tag of $3.5 million making it the most expensive drug to date. In …See details»